

Experiment Number: 99930-93
Test Type: SPECIAL STUDY
Route: DOSED FEED
Species/Strain: Rat/CD

**P05: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS
ABRIDGED) (a)**

Test Compound: Endocrine disruptor (Genistein)
CAS Number: 446-72-0

Date Report Requested: 10/17/2014
Time Report Requested: 12:51:41
First Dose M/F: NA / NA
Lab: NCTR

C Number: MG96005
Lock Date: Not Entered.
Cage Range: All
Date Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: All
Study Gender: Both
PWG Approval Date: NONE

Experiment Number: 99930-93
 Test Type: SPECIAL STUDY
 Route: DOSED FEED
 Species/Strain: Rat/CD

P05: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)

Test Compound: Endocrine disruptor (Genistein)
 CAS Number: 446-72-0

Date Report Requested: 10/17/2014
 Time Report Requested: 12:51:41
 First Dose M/F: NA / NA
 Lab: NCTR

CD Rat MALE	F3 0PPM	F3 5PPM TO CTL	F3 100PPM TO CTL	F3 500PPM TO CTL
Disposition Summary				
Animals Initially In Study	52	50	50	50
Early Deaths				
Moribund	8		11	4
Natural Death	11	7	5	8
Survivors				
Moribund		1		
Natural Death			1	2
Terminal Sacrifice	33	42	33	36
Animals Examined Microscopically	52	50	49	49

ALIMENTARY SYSTEM

Esophagus	(49)	(49)	(48)	(49)
Adventitia, Fibrous Histiocytoma, Metastatic, Uncertain Primary Site	1 (2%)			
Intestine Large, Cecum	(41)	(43)	(46)	(45)
Intestine Large, Colon	(41)	(43)	(46)	(45)
Adenocarcinoma	1 (2%)			
Intestine Large, Rectum	(38)	(42)	(38)	(38)
Leiomyosarcoma	1 (3%)			
Intestine Small, Duodenum	(41)	(43)	(46)	(43)
Adenocarcinoma	2 (5%)			
Intestine Small, Ileum	(40)	(42)	(45)	(43)
Intestine Small, Jejunum	(40)	(43)	(45)	(41)
Adenocarcinoma				1 (2%)
Liver	(49)	(47)	(47)	(48)
Carcinoma, Metastatic, Pancreas				1 (2%)
Hepatocellular Adenoma	1 (2%)			1 (2%)
Hepatocellular Carcinoma	1 (2%)	1 (2%)		

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 99930-93

Test Type: SPECIAL STUDY

Route: DOSED FEED

Species/Strain: Rat/CD

P05: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)

Test Compound: Endocrine disruptor (Genistein)

CAS Number: 446-72-0

Date Report Requested: 10/17/2014

Time Report Requested: 12:51:41

First Dose M/F: NA / NA

Lab: NCTR

CD Rat MALE	F3	0PPM	F3 5PPM TO CTL	F3 100PPM TO CTL	F3 500PPM TO CTL
Mesentery	(0)		(1)	(0)	(0)
Pancreas	(45)		(47)	(48)	(47)
Acinar Cell, Adenoma				2 (4%)	
Carcinoma					1 (2%)
Salivary Glands	(49)		(47)	(47)	(48)
Carcinoma, Metastatic, Pancreas					1 (2%)
Fibrous Histiocytoma, Metastatic, Uncertain Primary Site	1 (2%)				
Stomach, Forestomach	(44)		(45)	(48)	(47)
Stomach, Glandular	(41)		(43)	(46)	(46)
Tongue	(0)		(0)	(1)	(0)
CARDIOVASCULAR SYSTEM					
Blood Vessel	(51)		(50)	(49)	(47)
Fibrous Histiocytoma, Metastatic, Uncertain Primary Site	1 (2%)				
Heart	(51)		(48)	(49)	(47)
Pericardium, Fibrous Histiocytoma, Metastatic, Uncertain Primary Site	1 (2%)				
ENDOCRINE SYSTEM					
Adrenal Cortex	(48)		(47)	(47)	(47)
Adenoma				1 (2%)	
Adrenal Medulla	(48)		(46)	(47)	(45)
Pheochromocytoma Benign	4 (8%)		3 (7%)	4 (9%)	2 (4%)
Pheochromocytoma Malignant	1 (2%)				
Islets, Pancreatic	(45)		(49)	(48)	(48)
Adenoma	3 (7%)		3 (6%)	2 (4%)	
Carcinoma				1 (2%)	
Parathyroid Gland	(41)		(46)	(48)	(43)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 99930-93

Test Type: SPECIAL STUDY

Route: DOSED FEED

Species/Strain: Rat/CD

P05: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)

Test Compound: Endocrine disruptor (Genistein)

CAS Number: 446-72-0

Date Report Requested: 10/17/2014

Time Report Requested: 12:51:41

First Dose M/F: NA / NA

Lab: NCTR

CD Rat MALE	F3	0PPM	F3 5PPM TO CTL	F3 100PPM TO CTL	F3 500PPM TO CTL
Adenoma				1 (2%)	
Pituitary Gland	(49)		(46)	(48)	(48)
Pars Distalis, Adenoma	16 (33%)		18 (39%)	17 (35%)	14 (29%)
Pars Distalis, Adenoma, Multiple	1 (2%)				1 (2%)
Thyroid Gland	(44)		(46)	(46)	(45)
Bilateral, C Cell, Adenoma	1 (2%)				
C Cell, Adenoma	1 (2%)				1 (2%)
C Cell, Carcinoma					1 (2%)
GENERAL BODY SYSTEM					
Tissue NOS	(0)		(1)	(0)	(2)
Abdominal, Sarcoma			1 (100%)		
Squamous Cell Carcinoma					1 (50%)
GENITAL SYSTEM					
Coagulating Gland	(44)		(43)	(47)	(45)
Sarcoma, Metastatic, Uncertain Primary Site				1 (2%)	
Epididymis	(49)		(48)	(49)	(47)
Preputial Gland	(48)		(48)	(47)	(47)
Carcinoma				1 (2%)	
Squamous Cell Carcinoma				5 (11%)	3 (6%)
Prostate	(6)		(8)	(6)	(4)
Prostate, Dorsal Lobe	(51)		(47)	(47)	(48)
Adenocarcinoma					1 (2%)
Sarcoma, Metastatic, Uncertain Primary Site				1 (2%)	
Prostate, Ventral Lobe	(48)		(46)	(48)	(47)
Adenoma				1 (2%)	1 (2%)
Rete Testes	(47)		(48)	(46)	(41)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 99930-93

Test Type: SPECIAL STUDY

Route: DOSED FEED

Species/Strain: Rat/CD

P05: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)

Test Compound: Endocrine disruptor (Genistein)

CAS Number: 446-72-0

Date Report Requested: 10/17/2014

Time Report Requested: 12:51:41

First Dose M/F: NA / NA

Lab: NCTR

CD Rat MALE	F3	0PPM	F3 5PPM TO CTL	F3 100PPM TO CTL	F3 500PPM TO CTL
Seminal Vesicle	(43)		(43)	(47)	(45)
Adenoma				1 (2%)	
Sarcoma				1 (2%)	
Sarcoma, Metastatic, Uncertain Primary Site				1 (2%)	
Testes	(50)		(50)	(48)	(49)
Interstitial Cell, Adenoma	1 (2%)		1 (2%)		
Seminoma Benign	1 (2%)				
HEMATOPOIETIC SYSTEM					
Bone Marrow	(48)		(48)	(48)	(46)
Carcinoma, Metastatic, Pancreas					1 (2%)
Lymph Node	(13)		(9)	(18)	(12)
Lumbar, Squamous Cell Carcinoma, Metastatic, Preputial Gland					1 (8%)
Lymph Node, Mandibular	(48)		(48)	(48)	(48)
Fibrous Histiocytoma, Metastatic, Uncertain Primary Site	1 (2%)				
Lymph Node, Mesenteric	(45)		(46)	(47)	(47)
Spleen	(50)		(49)	(48)	(47)
Carcinoma, Metastatic, Pancreas					1 (2%)
Sarcoma	1 (2%)		1 (2%)		
Thymus	(46)		(45)	(41)	(44)
Adventitia, Fibrous Histiocytoma, Metastatic, Uncertain Primary Site	1 (2%)				
INTEGUMENTARY SYSTEM					
Mammary Gland	(39)		(43)	(41)	(41)
Adenocarcinoma				1 (2%)	
Fibroadenoma					2 (5%)
Fibroma					2 (5%)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 99930-93
Test Type: SPECIAL STUDY
Route: DOSED FEED
Species/Strain: Rat/CD

P05: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)

Test Compound: Endocrine disruptor (Genistein)
CAS Number: 446-72-0

Date Report Requested: 10/17/2014
Time Report Requested: 12:51:41
First Dose M/F: NA / NA
Lab: NCTR

CD Rat MALE	F3 0PPM	F3 5PPM TO CTL	F3 100PPM TO CTL	F3 500PPM TO CTL
Skin	(49)	(50)	(48)	(49)
Basal Cell Adenoma				1 (2%)
Fibroma		1 (2%)		
Keratoacanthoma	1 (2%)			1 (2%)
Lipoma			1 (2%)	
Neurofibrosarcoma				1 (2%)
Schwannoma Malignant	1 (2%)			
Squamous Cell Carcinoma	1 (2%)		3 (6%)	
Squamous Cell Papilloma				1 (2%)
MUSCULOSKELETAL SYSTEM				
Bone	(0)	(0)	(0)	(1)
Chordoma				1 (100%)
Bone, Cranium	(2)	(0)	(0)	(0)
Bone, Femur	(50)	(50)	(48)	(49)
Skeletal Muscle	(1)	(0)	(0)	(1)
Carcinoma, Metastatic, Pancreas				1 (100%)
Fibrous Histiocytoma, Metastatic, Uncertain Primary Site	1 (100%)			
NERVOUS SYSTEM				
Brain, Brain Stem	(46)	(46)	(48)	(47)
Reticulosis Malignant				1 (2%)
Brain, Cerebellum	(46)	(46)	(48)	(46)
Astrocytoma Malignant	1 (2%)			
Reticulosis Malignant				1 (2%)
Brain, Cerebrum	(45)	(46)	(48)	(46)
Astrocytoma Malignant	1 (2%)	1 (2%)		
Reticulosis Malignant				1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 99930-93

Test Type: SPECIAL STUDY

Route: DOSED FEED

Species/Strain: Rat/CD

P05: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS
ABRIDGED) (a)

Test Compound: Endocrine disruptor (Genistein)

CAS Number: 446-72-0

Date Report Requested: 10/17/2014

Time Report Requested: 12:51:41

First Dose M/F: NA / NA

Lab: NCTR

CD Rat MALE	F3	0PPM	F3 5PPM TO CTL	F3 100PPM TO CTL	F3 500PPM TO CTL
RESPIRATORY SYSTEM					
Lung	(48)		(47)	(47)	(46)
Adenocarcinoma			1 (2%)		
Carcinoma, Metastatic, Pancreas					1 (2%)
Carcinoma, Metastatic, Uncertain Primary Site			1 (2%)		
Fibrous Histiocytoma, Metastatic, Uncertain Primary Site	1 (2%)				
Nose	(46)		(45)	(49)	(45)
Adventitia, Squamous Cell Carcinoma					1 (2%)
Squamous Cell Carcinoma			1 (2%)	1 (2%)	
Trachea	(45)		(44)	(48)	(44)
Adventitia, Fibrous Histiocytoma, Metastatic, Uncertain Primary Site	1 (2%)				
SPECIAL SENSES SYSTEM					
Eye	(37)		(43)	(38)	(39)
Adventitia, Squamous Cell Carcinoma					1 (3%)
Retrolbulbar, Carcinoma			1 (2%)		
Harderian Gland	(38)		(43)	(38)	(39)
Adenoma					1 (3%)
Adventitia, Squamous Cell Carcinoma					1 (3%)
Lacrimal Gland	(0)		(2)	(2)	(1)
Zymbal's Gland	(0)		(0)	(1)	(0)
Adenoma				1 (100%)	
URINARY SYSTEM					
Kidney	(46)		(49)	(47)	(47)
Adventitia, Carcinoma, Metastatic, Pancreas					1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 99930-93
Test Type: SPECIAL STUDY
Route: DOSED FEED
Species/Strain: Rat/CD

P05: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)

Test Compound: Endocrine disruptor (Genistein)
CAS Number: 446-72-0

Date Report Requested: 10/17/2014
Time Report Requested: 12:51:41
First Dose M/F: NA / NA
Lab: NCTR

CD Rat MALE	F3 0PPM	F3 5PPM TO CTL	F3 100PPM TO CTL	F3 500PPM TO CTL
Transit Epithe, Papilloma				1 (2%)
Urethra	(0)	(2)	(2)	(1)
Urinary Bladder	(45)	(43)	(47)	(46)
SYSTEMIC LESIONS				
Multiple Organ	*(52)	*(50)	*(49)	*(49)
Histiocytic Sarcoma			1 (2%)	
Leukemia	1 (2%)			
Leukemia Granulocytic				1 (2%)
Leukemia Mononuclear			1 (2%)	
Lymphoma Malignant	2 (4%)			
Mesothelioma Malignant		1 (2%)		1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 99930-93
 Test Type: SPECIAL STUDY
 Route: DOSED FEED
 Species/Strain: Rat/CD

P05: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)

Test Compound: Endocrine disruptor (Genistein)
 CAS Number: 446-72-0

Date Report Requested: 10/17/2014
 Time Report Requested: 12:51:41
 First Dose M/F: NA / NA
 Lab: NCTR

CD Rat MALE	F3 0PPM	F3 5PPM TO CTL	F3 100PPM TO CTL	F3 500PPM TO CTL
Tumor Summary for MALE				
Total Animals with Primary Neoplasms (b)	33	26	36	30
Total Primary Neoplasms	44	34	46	47
Total Animals with Benign Neoplasms	24	21	24	21
Total Benign Neoplasms	30	26	31	29
Total Animals with Malignant Neoplasms	14	8	13	13
Total Malignant Neoplasms	14	8	15	18
Total Animals with Metastatic Neoplasms	1	1	1	2
Total Metastatic Neoplasms	9	1	3	8
Total Animals with Malignant Neoplasms Uncertain Primary Site	1	1	1	
Total Animals with Neoplasms Uncertain - Benign or Malignant				
Total Uncertain Neoplasms				

END OF MALE DATA

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 99930-93
 Test Type: SPECIAL STUDY
 Route: DOSED FEED
 Species/Strain: Rat/CD

P05: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)

Test Compound: Endocrine disruptor (Genistein)
 CAS Number: 446-72-0

Date Report Requested: 10/17/2014
 Time Report Requested: 12:51:41
 First Dose M/F: NA / NA
 Lab: NCTR

CD Rat FEMALE	F3 0 PPM	F3 5PPM TO CTL	F3 100PPM TO CTL	F3 500PPM TO CTL
Disposition Summary				
Animals Initially In Study	53	50	50	50
Early Deaths				
Moribund	15	13	16	17
Natural Death	5	5	5	7
Survivors				
Moribund		1		
Natural Death		1		1
Terminal Sacrifice	33	30	29	25
Animals Examined Microscopically	53	50	50	50

ALIMENTARY SYSTEM

Esophagus	(53)	(50)	(50)	(48)
Intestine Large, Cecum	(52)	(50)	(50)	(49)
Intestine Large, Colon	(53)	(50)	(50)	(49)
Intestine Large, Rectum	(42)	(40)	(40)	(37)
Intestine Small, Duodenum	(52)	(50)	(50)	(49)
Intestine Small, Ileum	(51)	(48)	(47)	(48)
Intestine Small, Jejunum	(51)	(49)	(49)	(48)
Leiomyosarcoma		1 (2%)		
Liver	(53)	(50)	(50)	(49)
Cholangiocarcinoma		1 (2%)		
Fibrous Histiocytoma, Metastatic, Skin	1 (2%)			
Hepatocellular Adenoma			1 (2%)	
Mesentery	(0)	(1)	(1)	(0)
Oral Mucosa	(1)	(0)	(1)	(1)
Sarcoma	1 (100%)			1 (100%)
Pancreas	(52)	(50)	(50)	(49)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 99930-93

Test Type: SPECIAL STUDY

Route: DOSED FEED

Species/Strain: Rat/CD

P05: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)

Test Compound: Endocrine disruptor (Genistein)

CAS Number: 446-72-0

Date Report Requested: 10/17/2014

Time Report Requested: 12:51:41

First Dose M/F: NA / NA

Lab: NCTR

CD Rat FEMALE	F3 0 PPM	F3 5PPM TO CTL	F3 100PPM TO CTL	F3 500PPM TO CTL
Salivary Glands	(53)	(49)	(50)	(49)
Stomach	(0)	(1)	(0)	(0)
Stomach, Forestomach	(52)	(49)	(49)	(49)
Stomach, Glandular	(53)	(50)	(50)	(49)
CARDIOVASCULAR SYSTEM				
Blood Vessel	(53)	(50)	(50)	(49)
Heart	(53)	(50)	(50)	(49)
Schwannoma Nos			1 (2%)	
ENDOCRINE SYSTEM				
Adrenal Cortex	(53)	(50)	(50)	(49)
Adenoma		2 (4%)	1 (2%)	1 (2%)
Adrenal Medulla	(53)	(46)	(50)	(48)
Pheochromocytoma Benign	2 (4%)	1 (2%)		2 (4%)
Islets, Pancreatic	(52)	(50)	(50)	(49)
Adenoma	1 (2%)	2 (4%)	2 (4%)	1 (2%)
Parathyroid Gland	(53)	(41)	(47)	(46)
Pituitary Gland	(53)	(50)	(50)	(50)
Pars Distalis, Adenoma	41 (77%)	42 (84%)	42 (84%)	40 (80%)
Pars Distalis, Carcinoma		1 (2%)		
Thyroid Gland	(53)	(50)	(50)	(49)
C Cell, Adenoma		1 (2%)		3 (6%)
C Cell, Carcinoma		1 (2%)		
GENERAL BODY SYSTEM				
None				
GENITAL SYSTEM				
Clitoral Gland	(49)	(47)	(49)	(48)
Adenoma	2 (4%)		1 (2%)	

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 99930-93

Test Type: SPECIAL STUDY

Route: DOSED FEED

Species/Strain: Rat/CD

P05: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)

Test Compound: Endocrine disruptor (Genistein)

CAS Number: 446-72-0

Date Report Requested: 10/17/2014

Time Report Requested: 12:51:41

First Dose M/F: NA / NA

Lab: NCTR

CD Rat FEMALE	F3	0 PPM	F3 5PPM TO CTL	F3 100PPM TO CTL	F3 500PPM TO CTL
Adenoma	2	(4%)		1 (2%)	
Carcinoma				1 (2%)	
Fibrous Histiocytoma, Metastatic, Skin	1	(2%)			
Ovary		(53)	(50)	(49)	(49)
Tubulostromal Carcinoma	1	(2%)			
Yolk Sac Carcinoma					1 (2%)
Oviduct		(53)	(49)	(49)	(49)
Uterus		(53)	(50)	(50)	(49)
Adenocarcinoma	1	(2%)		1 (2%)	
Adenoma				1 (2%)	
Leiomyoma			1 (2%)		
Polyp Stromal	5	(9%)		5 (10%)	2 (4%)
Sarcoma Stromal				2 (4%)	
Vagina		(52)	(49)	(49)	(48)
HEMATOPOIETIC SYSTEM					
Bone Marrow		(53)	(50)	(50)	(49)
Lymph Node		(18)	(9)	(8)	(12)
Inguinal, Sarcoma, Metastatic, Skin	1	(6%)			
Lumbar, Fibrous Histiocytoma, Metastatic, Skin	1	(6%)			
Lumbar, Yolk Sac Carcinoma, Metastatic, Ovary					1 (8%)
Popliteal, Sarcoma, Metastatic, Skin	1	(6%)			
Renal, Yolk Sac Carcinoma, Metastatic, Ovary					1 (8%)
Sarcoma, Metastatic, Skin	1	(6%)			
Lymph Node, Mandibular		(53)	(49)	(50)	(49)
Lymph Node, Mesenteric		(53)	(50)	(50)	(49)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 99930-93

Test Type: SPECIAL STUDY

Route: DOSED FEED

Species/Strain: Rat/CD

P05: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)

Test Compound: Endocrine disruptor (Genistein)

CAS Number: 446-72-0

Date Report Requested: 10/17/2014

Time Report Requested: 12:51:41

First Dose M/F: NA / NA

Lab: NCTR

CD Rat FEMALE	F3	0 PPM	F3 5PPM TO CTL	F3 100PPM TO CTL	F3 500PPM TO CTL
Leiomyosarcoma, Metastatic, Intestine Small, Jejunum			1 (2%)		
Spleen	(53)		(50)	(50)	(49)
Thymus	(48)		(45)	(46)	(47)
Sarcoma	1 (2%)				
Thymoma Malignant	1 (2%)				1 (2%)
INTEGUMENTARY SYSTEM					
Mammary Gland	(53)		(49)	(50)	(50)
Adenocarcinoma	5 (9%)		6 (12%)	8 (16%)	10 (20%)
Adenocarcinoma, Multiple	2 (4%)		2 (4%)	2 (4%)	2 (4%)
Adenoma				1 (2%)	1 (2%)
Fibroadenoma	9 (17%)		9 (18%)	13 (26%)	19 (38%)
Fibroadenoma, Multiple	23 (43%)		11 (22%)	20 (40%)	9 (18%)
Skin	(53)		(50)	(50)	(50)
Fibrous Histiocytoma	1 (2%)				
Keratoacanthoma					1 (2%)
Sarcoma	1 (2%)				1 (2%)
Squamous Cell Carcinoma	1 (2%)				1 (2%)
MUSCULOSKELETAL SYSTEM					
Bone	(0)		(0)	(1)	(0)
Bone, Femur	(53)		(50)	(50)	(49)
Bone, Joint	(1)		(0)	(0)	(0)
Skeletal Muscle	(1)		(0)	(0)	(0)
NERVOUS SYSTEM					
Brain, Brain Stem	(53)		(50)	(50)	(49)
Brain, Cerebellum	(53)		(50)	(50)	(49)
Granular Cell Tumor Benign	1 (2%)				

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 99930-93

Test Type: SPECIAL STUDY

Route: DOSED FEED

Species/Strain: Rat/CD

P05: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)

Test Compound: Endocrine disruptor (Genistein)

CAS Number: 446-72-0

Date Report Requested: 10/17/2014

Time Report Requested: 12:51:41

First Dose M/F: NA / NA

Lab: NCTR

CD Rat FEMALE	F3	0 PPM	F3 5PPM TO CTL	F3 100PPM TO CTL	F3 500PPM TO CTL
Brain, Cerebrum	(53)		(50)	(50)	(49)
Carcinoma, Metastatic, Pituitary Gland					1 (2%)
Glioma Malignant, Mixed	1 (2%)				
Granular Cell Tumor Benign					1 (2%)
RESPIRATORY SYSTEM					
Lung	(53)		(50)	(50)	(49)
Fibrous Histiocytoma, Metastatic, Skin	1 (2%)				
Squamous Cell Carcinoma, Metastatic, Skin					1 (2%)
Nose	(53)		(50)	(50)	(49)
Squamous Cell Carcinoma	1 (2%)		1 (2%)		3 (6%)
Trachea	(53)		(50)	(50)	(49)
SPECIAL SENSES SYSTEM					
Eye	(43)		(41)	(40)	(38)
Harderian Gland	(43)		(40)	(40)	(38)
Lacrimal Gland	(0)		(1)	(0)	(0)
URINARY SYSTEM					
Kidney	(53)		(50)	(50)	(49)
Renal Tubule, Adenoma	1 (2%)			1 (2%)	
Urinary Bladder	(53)		(47)	(48)	(47)
SYSTEMIC LESIONS					
Multiple Organ	*(53)		*(50)	*(50)	*(50)
Leukemia Mononuclear			1 (2%)	1 (2%)	

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 99930-93
Test Type: SPECIAL STUDY
Route: DOSED FEED
Species/Strain: Rat/CD

**P05: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS
ABRIDGED) (a)**

Test Compound: Endocrine disruptor (Genistein)
CAS Number: 446-72-0

Date Report Requested: 10/17/2014
Time Report Requested: 12:51:41
First Dose M/F: NA / NA
Lab: NCTR

CD Rat FEMALE	F3 0 PPM	F3 5PPM TO CTL	F3 100PPM TO CTL	F3 500PPM TO CTL
Tumor Summary for FEMALE				
Total Animals with Primary Neoplasms (b)	52	48	48	49
Total Primary Neoplasms	102	83	104	100
Total Animals with Benign Neoplasms	49	48	46	48
Total Benign Neoplasms	85	69	88	80
Total Animals with Malignant Neoplasms	16	12	14	17
Total Malignant Neoplasms	16	14	15	20
Total Animals with Metastatic Neoplasms	2	1		3
Total Metastatic Neoplasms	7	1		4
Total Animals with Malignant Neoplasms Uncertain Primary Site				
Total Animals with Neoplasms Uncertain - Benign or Malignant	1		1	
Total Uncertain Neoplasms	1		1	

**** END OF REPORT ****

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically